| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18821691 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 110 journal articles in the PubMed database | Email to a friend | | |
| Genovese MC, McKay JD, Nasonov EL, et al.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. [Journal Article, Research Support, Non-U.S. Gov't]
Arthritis Rheum 2008 Oct; 58(10):2968-80.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Maini RN, Taylor PC, Szechinski J, et al.
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. [JOURNAL ARTICLE]
Arthritis Rheum 2006 Aug 31; 54(9):2817-2829.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Nishimoto N, Miyasaka N, Yamamoto K, et al.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. [JOURNAL ARTICLE]
Mod Rheumatol 2008 Nov 1.
Abstract | Full Citation | | Cohen SB, Emery P, Greenwald MW, et al.
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. [JOURNAL ARTICLE]
Arthritis Rheum 2006 Aug 31; 54(9):2793-2806.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Furst DE, Schiff MH, Fleischmann RM, et al.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). [Clinical Trial, Journal Article, Randomized Controlled Trial]
J Rheumatol 2003 Dec; 30(12):2563-71.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Emery P, Keystone E, Tony HP, et al.
IL-6 Receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre Randomised Placebo Controlled Trial. [JOURNAL ARTICLE]
Ann Rheum Dis 2008 Jul 14.
Abstract | Full Citation | | Smolen JS, Beaulieu A, Rubbert-Roth A, et al.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Lancet 2008 Mar 22; 371(9617):987-97.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lambert CM, Sandhu S, Lochhead A, et al.
Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Arthritis Rheum 2004 Feb; 50(2):364-71.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al.
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. [Journal Article]
Arthritis Rheum 2006 May; 54(5):1390-400.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
